More on NXTS
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $4.99 |
|
|||
| Open | $5.34 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $5.34 | ||||
| Day Low | $5.07 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 5,060 | ||||
- Form 8-K Nexentis Technologies For: May 27
- Nexentis unit achieves drug discovery milestone with improved molecule
- Nexentis subsidiary hits drug discovery milestone for cancer treatment
- Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development
- Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development
- Nexentis subsidiary achieves drug discovery milestone
- Nexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery Milestone
- Nexentis receives U.S. trademark registration for MITOLINE algorithm
- Nexentis Technologies Announces U.S. Trademark Registration Approval for MitoCareX’s Algorithm Platform MITOLINE™
- Nexentis Technologies (NXTS) files $100M mixed shelf
Entities mentioned with NXTS
- Definitive Agreement | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Show More...
